Navamedic ASA (OSL: NAVA)

Market Cap	507.29M
Revenue (ttm)	543.49M
Net Income (ttm)	24.64M
Shares Out	17.43M
EPS (ttm)	1.38
PE Ratio	21.02
Forward PE	15.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,883
Open	28.80
Previous Close	29.10
Day's Range	28.80 - 29.10
52-Week Range	28.50 - 43.90
Beta	0.48
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2024

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 45
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2023, Navamedic ASA's revenue was 512.00 million, an increase of 33.98% compared to the previous year's 382.14 million. Earnings were 3.30 million, a decrease of -88.77%.